Who pays, and what do we get?

Sixteen documents, no single case or bill, and a fight that mostly plays out across reports that never address each other by name. CBO, CMS, KFF, OECD, and RAND supply the numbers both sides invoke. PNHP, the Commonwealth Fund, and Himmelstein and Woolhandler make the case for universal coverage. Cato, Heritage, Fraser, and PhRMA make the case for a market-based system. Hover a card to see the assumption underneath it, click it for the full exchange, and ask which claims are actually arguing with each other and which are simply describing different things.

Question

Market-based/reform side Universal-coverage/single-payer side Neutral or contested findings both sides invoke

Color marks the side of the volley, not who is right. K marks a source that is neutral either because it is a single official or contracted estimate both sides cite (CBO, CMS, OECD, RAND, KFF), or because no competing estimate of the same measurement exists in this source set. The Commonwealth Fund and Himmelstein/Woolhandler carry the D label in every card regardless of whether that specific card's finding cuts toward or away from universal coverage, the same source-identity discipline applied to every K-tagged source.

A caution before you count silences. The market-based side holds 7 of 17 last words (41 percent) on 30 percent of cards, three of its four genuine last-word exchanges tracing to a single Cato essay (Michael F. Cannon, 2020) and the fourth to a single 2008 Cato paper (Michael Tanner). This concentration sits almost entirely in three lanes (universal entitlement, cost and financing, and wait times/rationing), the lanes with the most sustained back-and-forth; the other three lanes run close to even. It reflects which single essay happened to be written as a direct, wide-ranging rebuttal to the general case for single payer, not an even distribution of argumentative strength across the dataset. Separately: Tanner's 2008 paper is the only market-side voice in three lanes and now opens two of them, the oldest source setting the terms two lanes are argued against, while the universal-coverage side's material in those same two lanes runs current 2023-2024 data. No document in this source set offers a direct rebuttal to CBO's core claim that lower expected drug-manufacturer returns reduce new-drug output (Lane F); the closest card on the other side (PNHP's VA-pricing comparison) answers a different question entirely and is labeled as a parallel claim, not a rebuttal, for that reason.